# **ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARSCOV-2 INFECTION IN A UNIVERSITY HOSPITAL** 5PSQ-099

T. BLANCO ESPESO<sup>1</sup>, M. FLORIDO FRANCISCO<sup>1</sup>, R. SERRANO GIMÉNEZ<sup>1</sup>, M. RODRIGUEZ JORGE<sup>1</sup>. <sup>1</sup>HOSPITAL JUAN RAMÓN JIMÉNEZ, HOSPITAL PHARMACY, HUELVA, SPAIN

### **BACKGROUND AND IMPORTANCE**

The Spanish Medicines and Health Products Agency (AEMPS) has developed criteria to adapt the prescription of sotrovimab<sup>1</sup>, due to the pandemic situation and the limited drug stock.

### METHODS AND MATERIALS

## **AIM AND OBJECTIVES**

To describe the patients' population on treatment with sotrovimab and to assess the adequacy of this prescription according to the criteria established by the AEMPS.

J06-IMMUNE SERA AND

IMMUNOGLOBULINS

Retrospective observational study analysing all sotrovimab prescriptions in patients with SARS-CoV-2 infection from 01/25/2022 to 08/31/2022.

Demographic variables: sex, age. Data

	Omicron variant infection. SARS-CoV-2 vaccination status.	
	Serology [anti-S antibody<260 BAU (binding antibody units)/mL].	
	Groups	1: Immunocompromised, regardless of vaccination status.
		1.1. Solid organ transplantation.
AEMPS		1.2. Active myelotoxic chemotherapy.
criteria		1.3. Non-cytotoxic onco-haematological treatments with neutropenia/lymphopenia.
		1.4. Treatment with biological immunomodulators.
		1.5. Down's syndrome.
		1.6. Haematopoietic stem cell transplantation or CAR-T.
		1.7. HIV infection (with $\leq 200$ cells/mL).
		2: >80 years unvaccinated.
		3: >65 years (regardless of vaccination status) and $\geq 1$ risk factor for progression.

Prescriptions for sotrovimab were collected and analysed to determine whether they met the criteria and whether they were accepted. Data collected from electronic medical records and processed using Excel2019<sup>®</sup>.



VACCINATION STATUS







Ten per cent of the applications did not meet the criteria: four of them were not accepted (patients did not belong to any risk group); one was accepted, although it was a well-controlled HIV.

## CONCLUSIONS AND RELEVANCE

The main profile of patients treated with sotrovimab is men with solid organ transplantation, vaccinated and with negative immunity to SARS-CoV-2. Although the appropriateness of the prescription is high, it is necessary to continue protocolising the use of this drug to ensure its rational use.

# **REFERENCES AND/OR ACKNOWLEDGEMENTS**

1.https://www.aemps.gob.es/medicamentos-de-uso-humano/acceso-a-medicamentos-en-situaciones-especiales/criterios-paravalorar-la-administracion-de-las-nuevas-alternativas-terapeuticas-antivirales-frente-a-la-infeccion-por-sars-cov-2/





